Published in Dis Markers on November 18, 2015
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med (2000) 13.24
The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer (2005) 5.98
Role of chemokines in tumor growth. Cancer Lett (2007) 3.36
Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res (1989) 3.25
T and Tn, general carcinoma autoantigens. Science (1984) 3.10
Humoral immunity, inflammation and cancer. Curr Opin Immunol (2007) 2.68
Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol (2008) 2.52
Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med (Berl) (1997) 2.21
Polarized immune responses differentially regulate cancer development. Immunol Rev (2008) 1.95
Antibodies, Fc receptors and cancer. Curr Opin Immunol (2007) 1.89
Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res (2010) 1.79
The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression. Glycoconj J (2007) 1.74
The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res (2001) 1.71
Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteomics (2006) 1.56
A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology (2008) 1.55
N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J Proteome Res (2012) 1.46
Novel glycan biomarkers for the detection of lung cancer. J Proteome Res (2011) 1.33
A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics (2009) 1.24
Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. Neoplasia (2006) 1.23
Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proc Natl Acad Sci U S A (2014) 1.19
Analyzing antibody-Fc-receptor interactions. Methods Mol Biol (2008) 1.19
Mechanisms of cancer-associated glycosylation changes. Front Biosci (Landmark Ed) (2012) 1.14
Natural antibodies and cancer. J Autoimmun (2007) 1.13
The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol (2012) 1.11
Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review. J Autoimmun (2015) 1.11
Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J (2011) 1.08
Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer. Gynecol Oncol (2001) 1.07
Autoantibodies against tumor-related antigens: incidence and biologic significance. Hum Immunol (2010) 1.07
Immunoreactive T and Tn antigens in malignancy: role in carcinoma diagnosis, prognosis, and immunotherapy. Transfus Med Rev (2000) 1.04
Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Acta Oncol (2007) 1.02
Anti-Thomsen-Friedenreich-Ag (anti-TF-Ag) potential for cancer therapy. Front Biosci (Schol Ed) (2012) 1.00
T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced breast carcinoma. Cancer Detect Prev (1995) 1.00
Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy? Autoimmun Rev (2008) 0.98
Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's). Arthritis Rheum (2011) 0.94
Thomsen-Friedenreich antigen presents as a prognostic factor in colorectal carcinoma: A clinicopathologic study of 264 patients. Cancer (2000) 0.94
Prognostic impact of Thomsen-Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients. Breast Cancer Res Treat (2006) 0.91
Increasing the α 2, 6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer. Gut Liver (2013) 0.88
Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells. Int J Exp Pathol (2010) 0.88
Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients. World J Gastroenterol (2013) 0.86
Stimulation of proliferation in human colon cancer cells by human monoclonal antibodies against the TF antigen (galactose beta1-3 N-acetyl-galactosamine). Int J Cancer (1997) 0.85
Autoantibodies targeting tumor-associated antigens in metastatic cancer: Sialylated IgGs as candidate anti-inflammatory antibodies. Oncoimmunology (2013) 0.84
Postoperative change of anti-Thomsen-Friedenreich and Tn IgG level: the follow-up study of gastrointestinal cancer patients. World J Gastroenterol (2008) 0.83
Natural IgM and IgG antibodies to Thomsen-Friedenreich (T) antigen in serum of patients with gastric cancer and blood donors--relation to Lewis (a,b) histo-blood group phenotype. Acta Oncol (1999) 0.82
The lower level of natural anti-Thomsen-Friedenreich antigen (TFA) agglutinins in sera of patients with gastric cancer related to ABO(H) blood-group phenotype. Int J Cancer (1995) 0.80
The Thomsen-Friedenreich antigen and alphaGal-specific human IgG glycoforms: concanavalin A reactivity and relation to survival of cancer patients. Immunol Invest (2009) 0.80
The relation of the level of serum anti-TF, -Tn and -alpha-Gal IgG to survival in gastrointestinal cancer patients. Int J Med Sci (2013) 0.79
Increased sialylation of anti-Thomsen-Friedenreich antigen (CD176) antibodies in patients with gastric cancer: a diagnostic and prognostic potential. Biomed Res Int (2014) 0.77
The presence and clinical implications of α-2,6-galactose-linked sialic acids in non-small-cell lung cancer brain metastases--preliminary study. Folia Histochem Cytobiol (2014) 0.76